Ann: Phase I Clinical Trial R327 Advances to High Dose Cohort, page-11

I think the share price is holding quite well above a resistance/support level of 90c for now but all will depend on how they detail the journey from here.
I don't fully understand the process of getting drugs to market and obviously this is not a simple process. That being said it seems the company still has significant funds to proceed current programmes.
The big unknown right now seems to be what is the plan and timeline from here. From my point of view I would have thought the priority would be to get at least one product approved and to market as soon as possible to generate income and boost investor interest. The logical candidate would appear to be burns treatment assuming they complete current phase 1-2 trial successfully.This would hopefully provide cash and boost share price, both of which would reduce dilution if further funds are required.
I think a big boost to share price might be provided if they can clarify how much work is required to get this burns treatment approved and to market. Is it simply the completion of phase 3 required, or is the current phase 1-2 just a small test case and does it need to be repeated with much more data/larger patient cohort.

it seems sepsis commercialisation is still a few years away. Is burns treatment (or any other application) any closer to market? Once this becomes clearer I suspect share price might start to make it's next move.